Synthetic Biologics is developing cutting-edge therapeutics to treat pathogen-specific diseases.
Our two leading candidates are:
SYN-004 (ribaxamase) to prevent C. difficile infection and antibiotic-associated diarrhea
SYN-010 to treat irritable bowel syndrome with constipation (IBS-C)
-- Conference Call Scheduled for Thursday, May 4, 2017 at 4:30 p.m. EDT -- ROCKVILLE, Md., April, 26, 2017 /PRNewswire/ --